{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:19:04Z","timestamp":1791494344647,"version":"4.3.4"},"reference-count":43,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2023J01552"],"award-info":[{"award-number":["2023J01552"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To examine the cost\u2010effectiveness of adding finerenone to standard of care (SoC) for treating type 2 diabetes mellitus (T2DM)\u2010related chronic kidney disease (CKD) in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Based on the clinical data analysed by FIDELITY, we referenced the validated FINE\u2010CKD model (Markov model) to evaluate the cost\u2010effectiveness of SoC versus SoC\u2009+\u2009finerenone from the perspective of US payers. The model was cycled for 35\u2009years in 4\u2010month\u2009cycles, with cost and utility values derived from the published literature. The primary outcomes were incremental cost\u2010effectiveness ratio (ICER) and quality\u2010adjusted life years (QALYs). Deterministic and probabilistic sensitivity analyses were conducted to assess the robustness of the base\u2010case results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The treatment strategy of finerenone plus SoC led to gains of 6.95 QALYs and had a lifetime cost of $491\u2009745.31. Compared to SoC, that strategy yielded 0.48 more QALYs at an added cost of $65\u2009305.72. The ICER for finerenone was $135\u2009257.06 per QALY, which is below the willingness\u2010to\u2010pay threshold of United States ($150\u2009000\/QALY). The results were sensitive to the hazard ratios associated with the efficacy of finerenone and its cost. Probabilistic sensitivity analyses showed that the probability that finerenone plus SoC would be cost\u2010effective was 57.6%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For patients with T2DM\u2010related CKD, adding finerenone to SoC may be a cost\u2010effective option in the United States. Reasonable price reductions for finerenone could potentially benefit more patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.15997","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T05:00:57Z","timestamp":1728363657000},"page":"165-173","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cost\u2010effectiveness of finerenone added to standard of care for patients with type 2 diabetes\u2010related chronic kidney disease in the United States"],"prefix":"10.1111","volume":"27","author":[{"given":"Cailin","family":"Zheng","sequence":"first","affiliation":[{"name":"School of Pharmacy Fujian Medical University  Fuzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinneng","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Pharmacy Fujian Medical University  Fuzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Fujian Medical University Union Hospital  Fuzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2443-1203","authenticated-orcid":false,"given":"Xiaoxia","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital  Fuzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiong","family":"Huang","sequence":"additional","affiliation":[{"name":"School of Pharmacy Fujian Medical University  Fuzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingbin","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Pharmacy Fujian Medical University  Fuzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Pharmacy Fujian Medical University  Fuzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30045-3"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14401"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2207018"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-023-00877-z"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.063374"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.09.003"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa736"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01599-7"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab777"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110956"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0027"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad192"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3024"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02204-0"},{"issue":"20","key":"e_1_2_10_17_1","first-page":"S375","article-title":"FINE\u2010CKD model to evaluate economic value of finerenone in patients with chronic kidney disease and type 2 diabetes","volume":"27","author":"Pochopie\u0144 MT","year":"2021","journal-title":"Am J Manag Care"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-02053-6"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00835-z"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000149"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041031"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15201"},{"issue":"1","key":"e_1_2_10_23_1","first-page":"1","article-title":"United States life tables, 2020","volume":"71","author":"Arias E","year":"2022","journal-title":"Natl Vital Stat Rep"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61350-6"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.12.034"},{"key":"e_1_2_10_26_1","unstructured":"United States Renal Data System (USRDS).2022 USRDS Annual Data Report: Epidemiology of kidney disease in the United States.2022https:\/\/usrds-adr.niddk.nih.gov\/2022Accessed 18 July 2023."},{"key":"e_1_2_10_27_1","unstructured":"Centers for Medicare and Medicaid Services (CMS).NADAC (National Average Drug Acquisition Cost).2023https:\/\/data.medicaid.gov\/dataset\/4a00010a-132b-4e4d-a611-543c9521280fAccessed 12 January 2024."},{"issue":"20","key":"e_1_2_10_28_1","first-page":"S369","article-title":"Medical costs for managing chronic kidney disease and related complications in patients with chronic kidney disease and type 2 diabetes","volume":"27","author":"Betts KA","year":"2021","journal-title":"Am J Manag Care"},{"key":"e_1_2_10_29_1","unstructured":"Us Bureau of Labor Statistics.CPI Inflation Calculator.2023https:\/\/www.bls.gov\/data\/inflation_calculator.htmAccessed 24 November 2023."},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12195"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165675"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-2478"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X06290495"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/1741826711406616"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2013.12.003"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz106.FP374"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.04.079"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.1505"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac198"},{"key":"e_1_2_10_40_1","doi-asserted-by":"crossref","unstructured":"Scottish Medicines Consortium. Finerenone (Kerendia\u00ae) is accepted for use within NHSScotland.2022https:\/\/www.scottishmedicines.org.uk\/medicines-advice\/finerenone-kerendia-full-smc2486Accessed 3 February 2024.","DOI":"10.51731\/cjht.2023.609"},{"key":"e_1_2_10_41_1","unstructured":"(NICE) NIfHaCE.Single technology appraisal Finerenone for treating chronic kidney disease in people with type 2 diabetes [ID3773].2023https:\/\/www.nice.org.uk\/guidance\/ta877\/evidenceAccessed 3 February 2024."},{"key":"e_1_2_10_42_1","volume-title":"Finerenone (Kerendia): CADTH Reimbursement Review: Therapeutic Area: Chronic Kidney Disease","year":"2023"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(23)00570-3"},{"issue":"6","key":"e_1_2_10_44_1","first-page":"S104","article-title":"Validation of the FINE\u2010CKD model for future health technology assessments for finerenone in patients with chronic kidney disease and type 2 diabetes","volume":"28","author":"Pochopie\u0144 M","year":"2022","journal-title":"Am J Manag Care"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.15997","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/full-xml\/10.1111\/dom.15997","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.15997","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T06:25:17Z","timestamp":1771309517000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.15997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1111\/dom.15997"],"URL":"https:\/\/doi.org\/10.1111\/dom.15997","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"2024-06-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}